Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

K-115 is safe and reduces intraocular pressure in clinical settings

May 4, 2011

12D03 targets mutant epidermal growth factor receptor and has antitumor activity

May 4, 2011

Immunocytokine C2-2b-2b targets IFN-alpha-2b to tumor sites with enhanced antiproliferative activity

May 4, 2011

SNP in CDKN2BAS locus correlates with susceptibility to Ph+ acute lymphoblastic leukemia

May 3, 2011

Topical AMA-0076 reduces intraocular pressure with low systemic exposure

May 3, 2011

SAR-397769 eye drops show efficacy in model of age-related macular degeneration

May 3, 2011

GBR-500 slows growth of prostate tumors in vivo

May 3, 2011

Efficacy of linagliptin in type 2 diabetes is independent of body mass index

May 3, 2011

Ang-2-VEGF CrossMab simultaneously inhibits tumor growth and angiogenesis

May 3, 2011

Phase IIb trial compares AR-12286 to latanoprost in ocular hypertension

May 2, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...